tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Malacoplakia D008287 1 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Lichen Nitidus D017513 1 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Lymphocele D008210 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Hand Injuries D006230 1 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Cutis Laxa D003483 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Myelitis D009187 1 associated lipids
IgG Deficiency D017099 1 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
Hepatopulmonary Syndrome D020065 1 associated lipids
Herpes Labialis D006560 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Polymyositis D017285 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Erythroplasia D004919 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
West Nile Fever D014901 1 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Arm Injuries D001134 1 associated lipids
Intussusception D007443 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Autoimmune Diseases of the Nervous System D020274 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Budd-Chiari Syndrome D006502 1 associated lipids
AIDS-Associated Nephropathy D016263 1 associated lipids
Oral Ulcer D019226 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Epididymitis D004823 1 associated lipids
Pruritus Vulvae D011539 1 associated lipids
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Migraine with Aura D020325 1 associated lipids
Porokeratosis D017499 1 associated lipids
Lentigo D007911 1 associated lipids
Mutism D009155 1 associated lipids
Amyloid Neuropathies D017772 1 associated lipids
Meningitis, Fungal D016921 1 associated lipids
Malocclusion, Angle Class II D008312 1 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Dysuria D053159 1 associated lipids
Denys-Drash Syndrome D030321 1 associated lipids
Akinetic Mutism D000405 1 associated lipids
Sleep Apnea, Central D020182 1 associated lipids
Orchitis D009920 1 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Ecthyma, Contagious D004474 1 associated lipids
Priapism D011317 1 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Neurodermatitis D009450 1 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Retrognathia D063173 1 associated lipids
Mediastinal Diseases D008477 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Poxviridae Infections D011213 1 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Lacerations D022125 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Tinea Capitis D014006 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Hernia, Ventral D006555 1 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Apraxias D001072 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Omland SH and Gniadecki R Psoriasis inversa: A separate identity or a variant of psoriasis vulgaris? Clin. Dermatol. pmid:26051061
Chia BK and Tey HL Systematic review on the efficacy, safety, and cost-effectiveness of topical calcineurin inhibitors in atopic dermatitis. Dermatitis pmid:25984688
Menéndez Valladares P et al. [Increased lipoprotein(a) in a paediatric patient associated with nephrotic syndrome]. Clin Investig Arterioscler pmid:27623226
Jefferson J et al. Follicular Mucinosis in a Male Adolescent with a History of Acute Myelogenous Leukemia and Graft-versus-Host Disease. Pediatr Dermatol pmid:26645410
Borda B et al. Early histopathological changes in new-onset diabetes after kidney transplantation. Transplant. Proc. pmid:25131129
Porubsky M et al. Excellent outcomes can be achieved in young pancreas transplant alone recipients by addition of sirolimus to maintenance immunosuppression regimen. Transplant. Proc. pmid:25131074
Liu JY et al. Tacrolimus Versus Cyclosporine as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation. Am J Ther pmid:25299636
Haroon N et al. Tacrolimus Toxicity With Minimal Clinical Manifestations: A Case Report and Literature Review. Am J Ther pmid:25730156
Krzyżowska K et al. No Significant Influence of Reduced Initial Tacrolimus Dose on Risk of Underdosing and Early Graft Function in Older and Overweight Kidney Transplant Recipients. Transplant. Proc. pmid:30056895
Zmonarski S et al. Expression of PBMC TLR4 in Renal Graft Recipients Who Experienced Delayed Graft Function Reflects Dynamic Balance Between Blood and Tissue Compartments and Helps Select a Problematic Patient. Transplant. Proc. pmid:30056893
Zulim LFDC et al. Comparison of the efficacy of 0.03% tacrolimus eye drops diluted in olive oil and linseed oil for the treatment of keratoconjunctivitis sicca in dogs. Arq Bras Oftalmol pmid:29995121
pmid:9123237
Kim K et al. Everolimus-Induced Systemic Serositis After Simultaneous Liver and Kidney Transplantation: A Case Report. Transplant. Proc. pmid:28104132
Yamamoto T et al. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report. Transplant. Proc. pmid:28104125
Ülkümen PK et al. Annular lichenoid dermatitis of youth in a 15-year-old boy: Topical tacrolimus as a treatment option. Indian J Dermatol Venereol Leprol pmid:27279324
Dedhia P et al. Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report. Transplant. Proc. pmid:28104134
Zhang J et al. Chemotherapy for De Novo Gastric Adenocarcinoma After Deceased Orthotopic Liver Transplantation: A Case Report. Transplant. Proc. pmid:28104131
Britto-Williams P and Pansare M Management of chronic idiopathic urticaria in childhood: are we on the same page? J Allergy Clin Immunol Pract pmid:24565627
Ishida S et al. Calcineurin Inhibitor-Induced Pain Syndrome in ABO-Incompatible Living Kidney Transplantation: A Case Report. Transplant. Proc. pmid:28104127
Liu JY et al. Sirolimus Versus Tacrolimus as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation. Am J Ther pmid:25569597
Norero B et al.  Conversion to mycophenolate mofetil monotherapy in liver recipients: Calcineurin inhibitor levels are key. Ann Hepatol pmid:28051798
Back JH et al. Antiproteinuric Effects of Green Tea Extract on Tacrolimus-Induced Nephrotoxicity in Mice. Transplant. Proc. pmid:26293093
Dall'Agnol DJ et al. Effects of immunosuppressive drugs on gastrointestinal transit of rats: effects of tacrolimus, cyclosporine, and prednisone. Transplant. Proc. pmid:25131057
Collier DS et al. FK-506 in experimental renal allografts. 1987 Transplant. Proc. pmid:2445063
First International Workshop on FK-506. A potential breakthrough in immunosuppression. Proceedings. 1987 Transplant. Proc. pmid:2445066
Tanaka H et al. Physicochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. 1987 Transplant. Proc. pmid:2445067
Honbo T et al. The oral dosage form of FK-506. 1987 Transplant. Proc. pmid:2445068
Tamura K et al. A highly sensitive method to assay FK-506 levels in plasma. 1987 Transplant. Proc. pmid:2445069
Venkataramanan R et al. Biopharmaceutical aspects of FK-506. 1987 Transplant. Proc. pmid:2445070
Kino T et al. Effect of FK-506 on human mixed lymphocyte reaction in vitro. 1987 Transplant. Proc. pmid:2445071
Goto T et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. 1987 Transplant. Proc. pmid:2445072
Zeevi A et al. Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. 1987 Transplant. Proc. pmid:2445073
Sanghvi A et al. FK-506 enhances cyclosporine uptake by peripheral blood lymphocytes. 1987 Transplant. Proc. pmid:2445074
Ochiai T et al. Prolongation of canine renal allograft survival by treatment with FK-506. 1987 Transplant. Proc. pmid:2445075
Todo S et al. Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. 1987 Transplant. Proc. pmid:2445076
Collier DS et al. Kidney transplantation in the dog receiving FK-506. 1987 Transplant. Proc. pmid:2445077
Calne R et al. Observations about FK-506 in primates. 1987 Transplant. Proc. pmid:2445078
Todo S et al. Orthotopic liver transplantation in dogs receiving FK-506. 1987 Transplant. Proc. pmid:2445079
Lim SM et al. Heterotopic heart transplantation in the rat receiving FK-506. 1987 Transplant. Proc. pmid:2445080
Murase N et al. Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. 1987 Transplant. Proc. pmid:2445081
Makowka L et al. The effect of FK-506 on hyperacute rejection in presensitized rats. 1987 Transplant. Proc. pmid:2445082
Ochiai T et al. Effects of FK-506 on xenotransplantation of the heart and skin in a mouse-rat combination. 1987 Transplant. Proc. pmid:2445083
Nalesnik MA et al. Toxicology of FK-506 in the Lewis rat. 1987 Transplant. Proc. pmid:2445084
Ochiai T et al. Histopathologic studies in renal transplant recipient dogs receiving treatment with FK-506. 1987 Transplant. Proc. pmid:2445085
Thiru S et al. Pathological studies in canine and baboon renal allograft recipients immunosuppressed with FK-506. 1987 Transplant. Proc. pmid:2445086
Kino T et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. 1987 J. Antibiot. pmid:2445721
Kino T et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. 1987 J. Antibiot. pmid:2445722
Ochiai T et al. Studies of the effects of FK506 on renal allografting in the beagle dog. 1987 Transplantation pmid:2447688
Ochiai T et al. Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. 1987 Transplantation pmid:2447689
Ochiai T et al. Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat. 1987 Transplant. Proc. pmid:2484094
Sawada S et al. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. 1987 J. Immunol. pmid:2442255
Inamura N et al. Immunosuppressive effect of FK506 on collagen-induced arthritis in rats. 1988 Clin. Immunol. Immunopathol. pmid:2446810
Inamura N et al. Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. 1988 Transplantation pmid:2447690
Ochiai T et al. Studies on FK506 in experimental organ transplantation. 1988 Transplant. Proc. pmid:2450414
Immunosuppression: FK506. 1988 Transplant. Proc. pmid:2450415
Todo S et al. Effect of FK506 in experimental organ transplantation. 1988 Transplant. Proc. pmid:2450416
Tsuchimoto S et al. [Orthotopic liver transplantation in the rat--immunosuppressive effect of FR100906 on the survival of liver allografts]. 1988 Nihon Geka Gakkai Zasshi pmid:2452341
Nakajima K et al. Prolongation of cardiac xenograft survival in rats treated with 15-deoxyspergualin alone and in combination with FK506. 1988 Transplantation pmid:2454521
Todo S et al. Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. 1988 Surgery pmid:2456627
Kawashima H et al. Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats. 1988 Invest. Ophthalmol. Vis. Sci. pmid:2458329
Warty V et al. FK506: a novel immunosuppressive agent. Characteristics of binding and uptake by human lymphocytes. 1988 Transplantation pmid:2458643
Hewitt CW and Black KS Comparative studies of FK506 with cyclosporine. 1988 Transplantation pmid:2458644
Woo J et al. Spleen lymphocyte populations and expression of activation markers in rats treated with the potent new immunosuppressive agent FK-506. 1988 Immunology pmid:2460401
Hatanaka H et al. FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. II. Fermentation, isolation and physico-chemical and biological characteristics. 1988 J. Antibiot. pmid:2461926
Inamura N et al. Immunosuppressive effect of FK506 on experimental allergic encephalomyelitis in rats. 1988 Int. J. Immunopharmacol. pmid:2463974
Hatanaka H et al. FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. I. Taxonomy of the producing strain. 1988 J. Antibiot. pmid:3198493
Yoshimura N et al. A new immunosuppressive agent, FK506, inhibits the expression of alloantigen-activated suppressor cells as well as the induction of alloreactivity. 1989 Transplant. Proc. pmid:2468202
Thomson AW et al. Immunosuppressive activity, T-cell subset analysis, and acute toxicity of FK-506 in rats. 1989 Transplant. Proc. pmid:2468203
Sanghvi A et al. Increased cyclosporine uptake by cells pretreated with FK506 and evidence for binding of both drugs to a common intracellular protein. 1989 Transplant. Proc. pmid:2468204
Takagishi K et al. Effects of FK-506 on collagen arthritis in mice. 1989 Transplant. Proc. pmid:2468205
Arita C et al. Effect of FK 506 (FR 900506) on collagen arthritis in rats: a preliminary report. 1989 Transplant. Proc. pmid:2468206
Morimoto T et al. Blood levels of FK506 after intramuscular and intravenous administration in dogs. 1989 Transplant. Proc. pmid:2468207
Tsuchimoto S et al. Orthotopic liver transplantation in rats receiving FK506. 1989 Transplant. Proc. pmid:2468208
Yokota K et al. Comparative studies of FK506 and cyclosporine in canine orthotopic hepatic allograft survival. 1989 Transplant. Proc. pmid:2468209
Inagaki K et al. Effects of FK506 and 15-deoxyspergualin in rat orthotopic liver transplantation. 1989 Transplant. Proc. pmid:2468210
Gudas VM et al. Comparison of the immunosuppressive and toxic effects of FK506 and cyclosporine in xenograft recipients. 1989 Transplant. Proc. pmid:2468211
Sato K et al. Pancreaticoduodenal allotransplantation with cyclosporine and FK506. 1989 Transplant. Proc. pmid:2468212
Watanabe K et al. Prolongation effect of a small dose of FK506, cyclosporine, or azathioprine on renal allografts in dogs treated with fractionated lymphoid irradiation and donor bone marrow cell infusion. 1989 Transplant. Proc. pmid:2468213
Sakamoto K et al. Analysis of long-term acceptance of xenografts in rats induced by short-term administration of FK506. 1989 Transplant. Proc. pmid:2468222
Nakajima K et al. Effects of 15-deoxyspergualin and FK506 on the histology and survival of hamster-to-rat cardiac xenotransplantation. 1989 Transplant. Proc. pmid:2468223
Ochiai T et al. Comparative studies on the immunosuppressive activity of FK506, 15-deoxyspergualin, and cyclosporine. 1989 Transplant. Proc. pmid:2468228
Yasunami Y et al. Effects of a novel immunosuppressive agent, FK-506, on islet allograft survival in the rat. 1989 Transplant. Proc. pmid:2468234
Kobayashi C et al. Suppression of corneal graft rejection in rabbits by a new immunosuppressive agent, FK-506. 1989 Transplant. Proc. pmid:2468254
Kuroki H et al. Experimental studies of vascularized allogeneic limb transplantation in the rat using a new immunosuppressive agent, FK-506: morphological and immunological analysis. 1989 Transplant. Proc. pmid:2468255
Arai K et al. Prolonged limb allograft survival with short-term treatment with FK-506 in rats. 1989 Transplant. Proc. pmid:2468256
Ishibashi M et al. Immunopharmacologic effects of immunosuppressive agents explored by a new effector monocyte generation assay. 1989 Transplant. Proc. pmid:2469228
Starzl TE et al. Liver transplantation: an unfinished product. 1989 Transplant. Proc. pmid:2469232
Hatanaka H et al. FK-506 related compounds produced by Streptomyces tsukubaensis No. 9993. 1989 J. Antibiot. pmid:2470720
Kay JE et al. Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506. 1989 Immunology pmid:2475433
Moriyama S [Experimental tracheal reconstruction by allotransplantation]. 1989 Nihon Kyobu Geka Gakkai Zasshi pmid:2475555
Freedman RB Immunosuppression. Convergence of drug action. 1989 Nature pmid:2477712
Siekierka JJ et al. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. 1989 Nature pmid:2477714
Harding MW et al. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. 1989 Nature pmid:2477715
Kay JE et al. The mechanism of action of the immunosuppressive drug FK-506. 1989 Cell. Immunol. pmid:2478301
Starzl TE et al. FK 506 for liver, kidney, and pancreas transplantation. 1989 Lancet pmid:2478846
Arai K et al. Limb allografts in rats immunosuppressed with FK506. I. Reversal of rejection and indefinite survival. 1989 Transplantation pmid:2479130
Francavilla A et al. Augmentation of rat liver regeneration by FK 506 compared with cyclosporin. 1989 Lancet pmid:2479802
Walliser P et al. Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506. 1989 Immunology pmid:2480331
Aoki M et al. [Histological observations of immunosuppressive effects of FK-506 in canine lung allotransplantation]. 1989 Bull Chest Dis Res Inst Kyoto Univ pmid:2482787
Kay JE and Benzie CR T lymphocyte activation through the C28 pathway is insensitive to inhibition by the immunosuppressive drug FK-506. 1989 Immunol. Lett. pmid:2483716